Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
1.
Biol Psychiatry ; 85(12): 1056-1064, 2019 06 15.
Artículo en Inglés | MEDLINE | ID: mdl-30954231

RESUMEN

BACKGROUND: Posttraumatic stress disorder (PTSD) is a stress disorder that develops in only some individuals following a traumatic event. Data suggest that a substantial fraction of women recover after sexual violence. Thus, the investigation of stress and antistress neuropeptides in this sample has the potential to inform the neurochemistry of resilience following trauma. Nociceptin is an antistress neuropeptide in the brain that promotes resilience in animal models of PTSD. METHODS: [11C]NOP-1A positron emission tomography was used to measure the in vivo binding to nociceptin receptors in 18 college women who had experienced sexual violence irrespective of whether they met DSM-5 diagnostic criteria for PTSD. [11C]NOP-1A data from 18 healthy control subjects were also included to provide a contrast with the sexual violence group. [11C]NOP-1A total distribution volume (VT) in the regions of interest were measured with kinetic analysis using the arterial input function. The relationships between regional VT and Clinician-Administered PTSD Scale for DSM-5 total symptom and subscale severity were examined using correlational analyses. RESULTS: No differences in [11C]NOP-1A VT were noted between the sexual violence and control groups. VT in the midbrain and cerebellum were positively correlated with PTSD total symptom severity in the past month before positron emission tomography. Intrusion/re-experiencing and avoidance subscale symptoms drove this relationship. Stratification of subjects by a DSM-5 PTSD diagnosis and contrasting their VT with that in control subjects showed no group differences. CONCLUSIONS: Decreased midbrain and cerebellum nociceptin receptors are associated with less severe PTSD symptoms. Medications that target nociceptin should be explored to prevent and treat PTSD.


Asunto(s)
Encéfalo/metabolismo , Receptores Opioides/metabolismo , Resiliencia Psicológica , Delitos Sexuales/psicología , Trastornos por Estrés Postraumático/metabolismo , Adulto , Encéfalo/fisiopatología , Cerebelo/metabolismo , Cerebelo/fisiopatología , Femenino , Humanos , Mesencéfalo/metabolismo , Mesencéfalo/fisiopatología , Tomografía de Emisión de Positrones , Trastornos por Estrés Postraumático/etiología , Estudiantes , Adulto Joven , Receptor de Nociceptina
2.
PLoS One ; 11(6): e0157867, 2016.
Artículo en Inglés | MEDLINE | ID: mdl-27322568

RESUMEN

Basic investigations link a Val158Met polymorphism (rs4680) in the catechol-O-methyltransferase (COMT) gene to not only its enzymatic activity, but also to its dopaminergic tone in the prefrontal cortex. Previous PET studies have documented the relationship between COMT Val158Met polymorphism and D1 and D2/3 receptor binding potential (BP), and interpreted them in terms of dopaminergic tone. The use of baseline dopamine D1 and D2/3 receptor binding potential (BPND) as a proxy for dopaminergic tone is problematic because they reflect both endogenous dopamine levels (a change in radiotracer's apparent affinity) and receptor density. In this analysis of 31 healthy controls genotyped for the Val158Met polymorphism (Val/Val, Val/Met, and Met/Met), we used amphetamine-induced displacement of [11C]FLB 457 as a direct measure of dopamine release. Our analysis failed to show a relationship between COMT genotype status and prefrontal cortical dopamine release. COMT genotype was also not predictive of baseline dopamine D2/3 receptor BPND.


Asunto(s)
Anfetamina/farmacología , Catecol O-Metiltransferasa/genética , Corteza Cerebral/metabolismo , Dopamina/metabolismo , Tomografía de Emisión de Positrones , Pirrolidinas/farmacología , Salicilamidas/farmacología , Adulto , Corteza Cerebral/diagnóstico por imagen , Demografía , Femenino , Genotipo , Humanos , Masculino , Receptores Dopaminérgicos/metabolismo
SELECCIÓN DE REFERENCIAS
Detalles de la búsqueda